---
title: "Varegacestat (AL102): Desmoid tumors"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors. Clinical evidence covers RINGSIDE part B, RINGSIDE part A, CA002-001, AL102-501, AL102-502, AL102-503, and 2 further headings. 758 evidence topics quoted from 177 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102): Desmoid tumors

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Varegacestat

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Desmoid tumors

<a id="topic-1.1.1-1"></a>

##### Summary: definition, etiology, incidence, and prevalence

- Desmoid tumor is a “rare and locally aggressive monoclonal, fibroblastic proliferation” with infiltrative growth, a tendency toward local recurrence, and an inability to metastasize. Of desmoid tumors, 85-90% are sporadic, and 85% of these result from somatic CTNNB1 mutations (Immunome Form 10-K); CTNNB1 mutations were observed in 117 of 138 tumors (85%) in one series, and one CTNNB1 alteration was found in 435 cases (84.3%) in the ALTITUDES cohort.
- Approximately 5–10% of desmoid tumors arise with familial adenomatous polyposis (FAP), and 39 of 519 participants (7.5%) in a Dutch nationwide pathology registry had FAP. Among patients with FAP, 36 of 328 (11.0%) in a U.S. community-based cohort and 66 of 735 (9%) in another cohort developed desmoid tumors; a family history of desmoids (30% vs 6.7%) and colorectal surgery were associated with higher risk. Antecedent trauma was verified in 164 participants (32.7%) in one series, including prior surgery in 98, and pregnancy and estrogen are listed as risk factors.
- Incidence estimates come from European studies: an increase from 2.10 to 5.36 per million people per year for extra-abdominal and abdominal wall tumors in the Netherlands (1993 to 2013); 3.42 per million person-years for sporadic tumors in the Netherlands (1999 to 2009); an average of 3.2 per 1,000,000 individuals per year in Denmark (2009 to 2018); 2.4–4.3 per million in Finland; and 5–6 cases per 1 million per year in the Desmoid Tumor Working Group guideline. A literature review estimated 3–5 cases per million person-years and identified no epidemiological study in the United States and no prevalence study.
- Most cases appear between ages 20 and 44, with 2.2–3.9 female cases for each male case; in Denmark, 76% of 179 participants were female and the median age at diagnosis was 38 years.
- Most U.S. figures are company estimates. SpringWorks Therapeutics (Form 10-K) estimates 1,000 to 1,650 new diagnoses each year, approximately 5,500 to 7,000 actively managed patients in any given year over the next decade (from market research with feedback from over 400 physicians), and approximately 11,000 patients receiving physician care annually (from ICD-10 claims between October 2023 and October 2024). Immunome states 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the U.S., citing Bektas et al. and an “Immunome Analysis”. A published estimate gives an annual U.S. incidence of 1000 patients.
- In Germany, the G-BA took into account the company dossier's figure of approximately 350 to 630 adults with progressing desmoid tumours requiring systemic treatment and described these numbers as subject to uncertainty.

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm); [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/); [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/); [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/); [Thomas et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42753019/); [Nieuwenhuis et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18237870/); [Hohenberger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37751183/); [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/); [van Broekhoven et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4531142/); [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/); [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/); [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/); [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf); [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)

<a id="topic-1.1.1-2"></a>

##### Summary: natural history, recurrence, and mortality

- Without treatment, an estimated 10–28% of desmoid tumors resolve spontaneously, 30% cycle through progression and resolution, 50% remain stable, and 10% progress rapidly.
- In a pooled analysis of three prospective observational studies of active surveillance (282 participants, median follow-up 53 months), 5-year treatment-free survival was 66%, and the 5-year crude cumulative incidences were 34% for RECIST progression and 34% for RECIST regression. In a United Kingdom cohort of 168 participants initially managed with active surveillance, 46% proceeded to treatment, after a median of 31 months.
- In the ALTITUDES nationwide prospective cohort (628 participants enrolled), the estimated 3-year event-free survival was 66.2%. In a prospective study of 771 cases, 2-year event-free survival was 53% after surgery and 58% with the wait-and-see approach (p = 0.415).
- After complete gross resection, 100 of 439 participants (23%) had recurrence, and 5-year local recurrence-free survival was 69% overall and 91% for abdominal wall tumors. Reported recurrence rates range from 24% to 77% for extremity tumors and 57–86% for intra-abdominal tumors in FAP, and 63% (103/163) of survey participants reported regrowth or recurrence after surgery.
- Desmoid tumors “typically have a limited impact on mortality” (SpringWorks Therapeutics). A Danish study reported a 5-year mortality rate of 7 per 1000 among patients with desmoid tumors and 5 per 1000 in a healthy matched cohort, with most deaths in patients with FAP. In a surgical series, 8 of 44 deaths were due to disease, all after R2 resection.
- Among 154 participants with intra-abdominal desmoid tumors, 5-year survival for stages I, II, III, and IV was 95%, 100%, 89%, and 76%, and 53% for stage IV patients with all identified risk factors; 5-year survival was 72% with home parenteral nutrition and 95% without it.
- Immunome's presentation states that approximately 50% of patients have desmoid tumors for more than 5 years, citing an ESMO Sarcoma 2024 poster.

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/); [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/); [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/); [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/); [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/); [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/); [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/); [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm); [Quintini et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22323009/); [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-1.1.1-3"></a>

##### Summary: symptoms and health-related quality of life

- Symptom presentation ranges from no symptoms to severe pain and functional limitation. Among 399 survey participants, signs and symptoms at diagnosis included an unexplained bump (60%), pain (57%), and fatigue (14%); tumor pain was documented in 57.4% of patients in the University of Utah Health network.
- Up to 63% of patients experience chronic pain, which leads to sleep disturbance in 73% of cases. In a cohort of 382 participants, the prevalence of pain was 36%, and pain at baseline was associated with poor quality of life, depression, and functional impairment.
- In concept elicitation interviews with 31 participants, fear (26 mentions), difficulty sleeping (24), anxiety (22), and depression (20) were frequently reported impacts; median disturbance ratings were 8.50 for hopelessness, 8.00 for depression, and 8.00 for financial difficulties.
- Among 235 participants in the United Kingdom and the Netherlands, 31% were in a high symptom burden cluster with clinically relevant lower HRQoL scores. In a study of 102 participants with desmoid tumors and 102 healthy controls, mean global health status was 65.58 among patients, and anxiety and depression were observed in 39.22% and 50% of patients. Anxiety and depression levels may be commensurate with those associated with malignant sarcomas.
- Survey participants with a current desmoid tumor reported significantly worse pain, fatigue, physical functioning, and sleep than those without one; among 322 respondents, 47% used NSAIDs and 19% used opioids for symptom management.
- In the NICE appraisal of nirogacestat, the DeFi trial did not collect EQ-5D data; the utility value for progressed disease was 0.263 in the company base case and 0.560 in the EAG base case, both drawn from soft-tissue sarcoma data.

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/); [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/); [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/); [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/); [Penel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883417/); [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/); [Garg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36350382/); [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-1.1.1-4"></a>

##### Summary: economic, family, and diagnostic testing burden

- A systematic literature review identified no studies evaluating the direct or indirect costs of patients with desmoid tumors. Within 3 years after diagnosis in Danish registers, patients had on average 1 inpatient and 7.1 outpatient visits and 7.5 days in hospital, compared with 0.8, 0.1, and 0.8 in the matched comparison cohort; 70% of surgically treated and 63% of non-surgically treated patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids in the 3 years after diagnosis.
- In the University of Utah Health network, patients averaged 2.4 desmoid-related outpatient visits per year, the median number of outpatient visits was 7.2 per patient per year during symptomatic disease, and 20.3% required desmoid-related hospitalization.
- In studies summarized by a systematic review, 26% of patients stopped working and 10% worked part time because of pain. An NHS Scotland costing of 10-year active surveillance estimated combined imaging and clinic costs exceeding £6500 per patient.
- The burden is “disproportionately borne by women of childbearing and working age”. The NICE committee noted effects on careers, relationships, social lives, the ability to have a family, and carers' quality of life. Pregnancy was associated with an increased risk of events at 24 months (HR = 2.09) in one cohort, and among 177 pregnancies in 157 women, progression during pregnancy ranged from 9.5% to 68.7% by group and spontaneous regression occurred in 23.7%.
- A prior misdiagnosis was reported by 41% (162/399) of survey participants, and 46% (58/126) of those with a misdiagnosis and surgery had surgery before a definitive diagnosis. In the Utah cohort, 29.1% potentially had a misdiagnosis, and hospitalization in the year before diagnosis was 25.6% among them vs 2.6% among others. Misdiagnosis rates may reach 30–40% during an initial work-up.
- CTNNB1 testing was documented in 6.7% of patients in the Utah cohort, “potentially due to cost and reimbursement issues”, and requested in 15.5% of cases at a United Kingdom specialist center. In the French RRePS network, expected 12-month costs per patient (2013 euros) were €8,791 with centralized histological review and €8,904 without it.

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/); [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/); [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/); [Saraf et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12191607/); [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [Debaudringhien et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9588892/); [Fiore et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40328165/); [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/); [Cojocaru et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33547536/); [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Varegacestat Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: regulatory status and development

- Immunome submitted a New Drug Application in April 2026 for varegacestat, an oral, once-daily gamma secretase inhibitor, “for the treatment of adults with desmoid tumors”. The FDA accepted it in July 2026, assigned a PDUFA target action date of April 28, 2027, and is reviewing it “consistent with its conventional procedures and timeline”.
- Immunome submitted a marketing authorization application to the EMA in October 2026, and the EMA validated it for review under the centralized procedure.
- The FDA granted orphan drug designation for the treatment of desmoid tumors on 11/02/2023 and has granted Fast Track designation for progressing desmoid tumors; Immunome gives no date for the Fast Track grant. For the EU orphan designation, Immunome states that the EMA granted it in July 2025 for desmoid tumors, while the EMA register lists designation EU/3/25/3127 for the treatment of soft tissue sarcoma on 22 August 2025.
- Immunome states that it has no drugs approved for commercial sale.
- Bristol-Myers Squibb conducted a phase 1 dose-escalation trial of the compound (BMS-986115) in patients with solid tumors, which enrolled one patient with desmoid fibromatosis. Ayala Pharmaceuticals designed RINGSIDE, a seamless phase 2/3 study; Immunome acquired the compound from Ayala in March 2024 and assumed a license agreement with Bristol-Myers Squibb dated November 29, 2017.

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm); [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/); [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/); [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/); [FDA orphan drug designation record for varegacestat (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=968423); [EMA orphan designation EU/3/25/3127 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3127); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-1.1.2-2"></a>

##### Summary: RINGSIDE Part B efficacy

- RINGSIDE Part B was a double-blind, placebo-controlled study in adults with progressing desmoid tumors per RECIST v1.1. It randomized 156 participants 1:1 to varegacestat 1.2 mg once daily (n=79) or placebo (n=77), stratified by tumor location (intra- vs. extra-abdominal). Enrollment ran from November 15, 2022 to February 14, 2024, and the primary analysis data cutoff was October 7, 2025. The study was sponsored and funded by Immunome and Ayala Pharmaceuticals, and its results are available as a congress abstract, congress presentations and posters, and Immunome releases.
- Primary endpoint, progression-free survival (radiographic progression by blinded independent central review per RECIST v1.1, or death): 7 events among 79 varegacestat participants and 29 among 77 placebo participants; median PFS was not estimable with varegacestat and 24.9 months with placebo. The hazard ratio is 0.16 (95% CI 0.07, 0.38; P<0.0001) in the abstract and presentation, and 0.16 (95% CI 0.071, 0.375; p<0.0001) in Immunome's topline release and topline presentation.
- Landmark PFS in the ESMO 2026 primary results poster: 94% (95% CI 85 to 98%) with varegacestat and 66% (95% CI 52 to 76%) with placebo at 1 year, and 89% (95% CI 78 to 95%) and 57% (95% CI 43 to 69%) at 2 years.
- Confirmed objective response rate (alpha-controlled secondary endpoint): 44 of 79 (55.7%) with varegacestat and 7 of 77 (9.1%) with placebo (P<0.0001) in the abstract and presentation, reported as 56% and 9% in Immunome's topline release. Complete responses occurred in 3 varegacestat and 1 placebo participants, and progressive disease as best response in 0 and 10 (13.0%). Median time to response was 8.2 months with varegacestat and 16.7 months with placebo; median duration of response was not reached in either arm.
- Tumor volume at Week 24 (alpha-controlled secondary endpoint): least-squares mean change of -109.6 cm3 with varegacestat and 122.8 cm3 with placebo (difference -232.4; P<0.0001). Median best percent change in tumor volume, not alpha-controlled, was -83.4% and 11.3%, and median best percent change in T2-weighted signal intensity was -100% and -12%.
- The abstract states that PFS “consistently favored VAR in all subgroups analyzed”; the presentation labels the poor-prognosis subgroup analysis as post hoc.

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/); [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-1.1.2-3"></a>

##### Summary: RINGSIDE Part B patient-reported outcomes

- Alpha-controlled secondary endpoint, patient-reported worst pain intensity at Week 12 (data cutoff October 7, 2025): least-squares mean change of -2.24 with varegacestat and +0.18 with placebo, a difference of -2.42 (P<0.0001). The presentation reports a difference of more than 2 points in favor of varegacestat from the first evaluation at Week 4. Mean baseline scores were 4.43 and 4.94.
- In exploratory analyses in the ESMO presentation (mixed model for repeated measures, nominal p values, clinically meaningful thresholds derived from the RINGSIDE population), the difference between arms in the GODDESS pain domain score was -2.32, -2.02, and -2.70 at weeks 12, 24, and 48 (threshold -1.62), and in the GODDESS TSS-5 symptom score -1.46, -1.43, and -2.09 (threshold -1.16).
- In the same presentation, the difference in the PROMIS Physical Function 10a T-score was +3.13, +5.84, and +6.54 at weeks 12, 24, and 48 (threshold +3.10). These results use a baseline that was “redefined post hoc to include PRO assessments completed on or before first dose”.
- Immunome's ESMO press release reports week 48 least-squares mean changes from baseline of -1.50 with varegacestat and +0.59 with placebo on the TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
- The number of participants with data declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, and physical function data for 37 and 26.

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf); [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf); [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-1.1.2-4"></a>

##### Summary: RINGSIDE Part B safety

- At the October 7, 2025 data cutoff, median duration of exposure was 20.3 months with varegacestat and 11.1 months with placebo. Adverse events occurred in 79 of 79 varegacestat participants (100%) and 70 of 77 placebo participants (91%); grade 3/4 adverse events in 57% and 17%; and serious adverse events in 25 (32%) and 7 (9%). The abstract reports that 95% of adverse events were grade 1-2 and that there were no grade 5 adverse events. The safety poster states “No deaths due to adverse events”, and Immunome's topline and corporate presentations state “There were no deaths on study”.
- The most frequent adverse events by preferred term, varegacestat versus placebo, were diarrhea (82% vs. 27%; grade 3 or higher in 10.1% with varegacestat), fatigue (44% vs. 23%), rash (43% vs. 12%), nausea (35% vs. 26%), and cough (34% vs. 5%). As a grouped term, rash occurred in 56 (70.9%) varegacestat and 13 (16.9%) placebo participants. Alopecia occurred in 33% and 4%, and hair color changes in 25% and 0.
- Among varegacestat participants, squamous cell carcinoma and keratoacanthoma were reported at grade 1 in 1.3%, grade 2 in 6.3%, and grade 3 in 1.3%, and ALT or AST elevations at grade 2 in 3.8% and grade 3 in 3.8%.
- Adverse events led to dose reduction in 63 (80%) varegacestat and 7 (9%) placebo participants, and dose interruptions occurred in 65% and 14%. Varegacestat doses were reduced to 0.9 mg in 60 participants (median time 3.7 months) and to 0.6 mg in 36 (median 7.3 months).
- Discontinuation due to adverse events occurred in 20% of varegacestat participants in all sources (16 participants in the abstract); for placebo it is 7% in the abstract (5 participants), presentation, and safety poster and 6% in the primary results poster.
- Ovarian toxicity occurred in 20 of 36 premenopausal women (56%) receiving varegacestat and in 5% with placebo, and led to no discontinuations. The abstract reports resolution in 11 of 20 (55%); the safety poster reports resolution in all 8 women off varegacestat with follow-up available (100%) and in 3 of 10 (30%) with ongoing treatment.

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf); [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-1.1.2-5"></a>

##### Summary: RINGSIDE Part A

- RINGSIDE phase II was an open-label, randomized, dose-finding trial. Between October 6, 2021 and July 15, 2022, it enrolled 42 adults with progressing desmoid tumors (14 per arm) at 21 academic medical centers in Australia, Korea, Spain, Israel, the Netherlands, the United Kingdom, and the United States, randomized 1:1:1 to varegacestat 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent. The primary endpoint was safety, and change in tumor volume at week 16 was the key efficacy evaluation. The study was supported by Immunome.
- Among 37 (88.1%) MRI-evaluable participants, median tumor volume change at week 16 was -51.91% with 1.2 mg once daily, -15.25% with 2 mg, and -9.50% with 4 mg; the least-squares mean reduction was statistically significant for 1.2 mg once daily only (-39.8%). Confirmed objective response rates during the randomized trial were 35.7%, 21.4%, and 21.4%, and 1.2 mg once daily was selected for phase III.
- As of January 6, 2025, 29 participants (69.0%) entered the open-label extension, where all received 1.2 mg once daily, and 12 remained on treatment. The confirmed objective response rate for all 42 participants was 57.1% (24 responders, 2 complete responses), median duration of response was not reached, and median exposure was 102.0 weeks.
- Earlier data cuts report other figures. As of April 10, 2024, one abstract reports objective response rates in the evaluable population of 75% (9 of 12) with 1.2 mg once daily and 64% (23 of 36) with all doses. Immunome's 10-K, describing data reported at ESMO in 2024, gives an intention-to-treat response rate of 55% across all doses and 64% for the 1.2 mg once-daily cohort. Median time on treatment as of April 10, 2024 is 25.4 months in one abstract and 23.1 months in another.
- Safety during the randomized trial: 96.5% of adverse events were grade 1 or 2, grade 3 adverse events occurred in 16 participants (38.1%), serious adverse events in six (14.3%), and no grade 4 or 5 events occurred. The most common were diarrhea (81.0%), nausea (50.0%), and fatigue (42.9%). Ovarian toxicity occurred in 12 of 23 women of childbearing potential (52.2%) and resolved in six (50%). Including the open-label extension, 14 participants (33.3%) had treatment-related grade 3 adverse events.
- Patient-reported outcomes were not analyzed because of limited data availability and small sample sizes.

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725); [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857); [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-1.1.2-6"></a>

##### Summary: phase 1 and clinical pharmacology

- In the Bristol-Myers Squibb phase 1 dose-escalation trial of BMS-986115 (36 treated participants with solid tumors; 0.3 to 2 mg once daily or 2 to 8 mg twice weekly), the maximum tolerated once-daily dose was 1.5 mg. No dose-limiting toxicity occurred in 5 evaluable participants at 1.2 mg once daily, and 2 mg once daily was not tolerated (dose-limiting toxicities in 3 of 5). The most frequent adverse events regardless of causality were diarrhoea (72%), nausea (69%), hypophosphataemia (67%), and fatigue (64%). The study was sponsored and funded by Bristol-Myers Squibb and “terminated early for business reasons”.
- The one participant with fibromatosis, treated at 1.5 mg once daily, achieved stable disease with maximum shrinkage of 16.5% after about 9 months.
- In that trial, BMS-986115 was rapidly absorbed (median Tmax 1 h to 3 h), the median half-life with once-daily dosing ranged from 17.24 h to 28.01 h, and the median accumulation ratio at 1.2 mg once daily was 3.66. The equally active metabolite BMT-100948 had a median AUCtau of 17% to 27% of the parent drug after multiple doses. Immunome's corporate presentation states a 78% longer half-life than nirogacestat, citing Immunome data on file.
- An exposure-response analysis presented at ESMO 2026 (198 RINGSIDE participants for efficacy; 157 treated participants, including 36 from the phase 1 trial, for safety) found that exposure was not a statistically significant predictor of PFS and ORR, and that “Dose reduction had no apparent impact on PFS.” Statistically significant exposure-response relationships were found for treatment-emergent serious adverse events and grade 2 or higher nausea/vomiting, fatigue, diarrhea, hypophosphatemia, and rash. The authors state that the analyses support 1.2 mg once daily as the recommended dose.
- Four phase 1 studies, three in healthy participants and one in participants with or without hepatic impairment, are listed as completed on ClinicalTrials.gov: an itraconazole interaction study (AL102-501, 22 participants), a cardiac repolarization study (AL102-502, 32 participants), a hepatic impairment study (AL102-503, 35 participants), and a mass balance study of [14C]varegacestat in 6 healthy men (AL102-504). A relative bioavailability and bioequivalence study of capsule formulations (VAR-505, estimated 44 participants) is recruiting. The cited sources report no results from these five studies.

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf); [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996); [ClinicalTrials.gov NCT06855264](https://clinicaltrials.gov/study/NCT06855264); [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315); [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852); [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Varegacestat

<a id="topic-1.1.3-1"></a>

##### Summary: price status and comparator prices

- Immunome reported in its third quarter 2026 Form 10-Q that it has “no drugs approved for commercial sale”. The report quotes no price, commercial dosage form, or launch date for varegacestat. Immunome's topline call presentation states “>90% anticipated payer coverage” and that orphan designation “has favorable pricing implications”.
- Nirogacestat (OGSIVEO) U.S. wholesale acquisition cost: $7,746.58 for each of the 100 mg and 150 mg tablet packages, in a SpringWorks Connecticut price disclosure dated 01/05/2026, which states that the WAC “may not represent actual transactional prices.” The prescribing information describes the package as one blister card with 14 tablets and gives a recommended dosage of 150 mg twice daily.
- Nirogacestat WAC at introduction: $29,000 for a 180-count bottle of 50 mg tablets, dated 12/4/2023 (Vermont Attorney General new drug report).
- England: anticipated list price of £15,189.04 per 56 pack of 150 mg tablets (company submission to NICE), available to the NHS with a discount whose size is commercial in confidence.
- Germany: G-BA annual treatment cost of €260,760.82 per patient after statutory rebates (LAUER-TAXE as last revised 1 February 2026), for the first year of treatment, with a treatment duration of one year (365 days) assumed when the product information specifies no maximum.

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm); [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf); [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf); [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf); [Vermont Attorney General new drug report (2024)](https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf); [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat); [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf); [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)

<a id="topic-1.1.3-2"></a>

##### Summary: eligible population

- A literature review (Bektas et al. 2023) identified no study of desmoid tumor prevalence; the incidence studies it found were all conducted in European countries. Most U.S. population figures in the report are company estimates.
- SpringWorks Therapeutics (Form 10-K, 2025): 1,000 to 1,650 new patients diagnosed each year in the United States; approximately 5,500 to 7,000 patients actively managed in any given year over the next decade, based on market research with feedback from over 400 physicians; and approximately 11,000 patients receiving physician care annually, from ICD-10 claims between October 2023 and October 2024.
- Immunome (October 2026 corporate presentation): 1,000-1,650 patients diagnosed each year and “10-11,000 actively managed patients in the US”, citing Bektas et al. (2023) and a footnote reading “Immunome Analysis”. The same presentation states that patients may receive “~1.5–2 years of treatment”, citing Immunome primary market research.
- England (NICE TA1199 resource impact): 223 people eligible for nirogacestat in year 1, with uptake of 50%, 60%, and 75% and 112, 117, and 125 people starting treatment in years 1, 2, and 3.
- Germany (G-BA): approximately 350 to 630 patients eligible for nirogacestat, taken from the company dossier and described by the G-BA as subject to uncertainty.

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/); [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [NICE TA1199 resource impact summary report (2026)](https://www.nice.org.uk/guidance/ta1199/resources/resource-impact-summary-report-17421211693/chapter/Resource-impact-summary-report); [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf); [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)

<a id="topic-1.1.3-3"></a>

##### Summary: health technology assessments and sales of nirogacestat

- NICE TA1199 recommends nirogacestat for progressing desmoid tumors that need systemic treatment in adults, only under the company's commercial arrangement. NICE reports that the company concluded an acceptable ICER would be around £35,000 per QALY gained, that the committee judged the estimates based on its preferred assumptions to be within the range considered an acceptable use of NHS resources, and that the exact cost-effectiveness estimates cannot be reported because of confidential discounts. The discount size, the De-Fi utilities mapped to EQ-5D, and the treatment-use estimates from SpringWorks market research are also confidential.
- The G-BA rated the extent of added benefit of nirogacestat as a “Hint for a minor additional benefit”.
- SpringWorks recorded U.S. net product revenue from OGSIVEO of $5.4 million for 2023 (sales began in December 2023) and $172.0 million for 2024.
- Merck KGaA, which acquired SpringWorks on July 1, 2025, reported Ogsiveo net sales of €134 million for 2025, €63 million for the first quarter of 2026, €75 million for the second quarter, and €78 million for the third quarter, when sales increased by 24.5% organically.
- The economic evaluations in the report concern comparators: the NICE model of nirogacestat, a SpringWorks-supported quality-adjusted time without symptoms or toxicity analysis of nirogacestat (Malaviya et al. 2025), and a cost-per-outcome analysis of sorafenib at Medicare Part D rates (Johns et al. 2023). No economic evaluation of varegacestat is quoted.

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation); [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf); [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm); [Merck KGaA annual report 2025 (2026)](https://reports.emdgroup.com/en/annualreport/2025/management-report/report-on-economic-position/course-of-business-and-economic-position/healthcare.html); [Merck KGaA press release, first quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q1-2026-13-05-2026.html); [Merck KGaA press release, second quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q2-2026-06-08-2026.html); [Merck KGaA press release, third quarter 2026 results (2026)](https://www.emdgroup.com/en/news/q3-2026-12-11-2026.html); [Malaviya et al. (2025)](https://springworkstx.com/wp-content/uploads/2025/11/Malaviya_ISPOR-EU_2025_Q-TWiST_POS.pdf); [Johns et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35112974/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

- Regulatory status: varegacestat, an oral, once-daily gamma secretase inhibitor, is not approved. Immunome submitted a New Drug Application in April 2026 for “the treatment of adults with desmoid tumors”; the FDA accepted it in July 2026 and assigned a PDUFA target action date of April 28, 2027. The EMA validated a marketing authorization application in October 2026. The FDA granted orphan drug designation in November 2023 and Fast Track designation for progressing desmoid tumors.
- Disease and unmet need: desmoid tumor is a “rare and locally aggressive monoclonal, fibroblastic proliferation” with an estimated incidence of 3–5 cases per million person-years; a literature review identified no U.S. epidemiological study, and most U.S. population figures are company estimates (SpringWorks: 1,000 to 1,650 new diagnoses a year and 5,500 to 7,000 actively managed patients from market research; Immunome: 10-11,000 actively managed patients). SpringWorks states that desmoid tumors “typically have a limited impact on mortality”; up to 63% of patients experience chronic pain, and 100 of 439 participants (23%) had recurrence after complete gross resection. The Desmoid Tumor Working Group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking, and Immunome states that the uptake of OGSIVEO shows the potential for gamma secretase inhibitors to address unmet need.
- Efficacy in RINGSIDE Part B (156 participants randomized to varegacestat 1.2 mg once daily, n=79, or placebo, n=77; data cutoff October 7, 2025): progression-free survival events occurred in 7 varegacestat and 29 placebo participants, with median PFS not estimable and 24.9 months. The hazard ratio is 0.16 (95% CI 0.07, 0.38) in the ASCO 2026 abstract and 0.16 (95% CI 0.071, 0.375) in Immunome's topline release. The confirmed objective response rate was 44 of 79 (55.7%) versus 7 of 77 (9.1%) in the abstract, and 56% versus 9% in the topline release. The difference in worst pain intensity at Week 12 was -2.42.
- Safety in RINGSIDE Part B: adverse events occurred in 100% of varegacestat and 91% of placebo participants, grade 3/4 adverse events in 57% and 17%, and diarrhea in 82% and 27%. Adverse events led to dose reduction in 80% of varegacestat participants and to discontinuation in 20% (placebo: 7% in the abstract, 6% in the primary results poster). Ovarian toxicity occurred in 20 of 36 premenopausal women (56%) receiving varegacestat; the abstract reports resolution in 11 of 20 (55%), and the safety poster reports resolution in all 8 women off treatment with follow-up available.
- Evidence limitations: Part B results are available as a congress abstract, congress presentations and posters, and Immunome releases; the ClinicalTrials.gov record lists no posted results. The study was sponsored by Immunome and Ayala Pharmaceuticals, and the comparator was placebo; Immunome states that “no head-to-head clinical trial has been conducted” against nirogacestat. The RINGSIDE primary endpoint counted radiographic progression by blinded independent central review, while the DeFi primary endpoint for nirogacestat also counted clinical progression. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo at the October 7, 2025 cutoff, and the patient-reported outcome analyses beyond the alpha-controlled secondary pain endpoint are exploratory.
- Approved comparator: OGSIVEO (nirogacestat), 150 mg twice daily, was first approved in the United States in 2023 and by the European Commission in August 2025. In DeFi, dose reductions due to adverse events occurred in 42% of nirogacestat recipients and ovarian dysfunction in 27 of 36 women of childbearing potential (75%). Its U.S. WAC is $7,746.58 per 14-tablet package (SpringWorks Connecticut disclosure dated 01/05/2026), after $29,000 per 180-count bottle of 50 mg tablets at introduction. NICE TA1199 recommends nirogacestat under a commercial arrangement, reports that the company concluded an acceptable ICER would be around £35,000 per QALY gained, and does not report the exact estimates because of confidential discounts; the G-BA found a “Hint for a minor additional benefit”.
- Not yet known: Immunome has “no drugs approved for commercial sale”, and the report quotes no prescribing information, commercial dosage strength, price, or launch date for varegacestat. A bioequivalence study of capsule formulations (VAR-505) is recruiting. The report quotes no cost-effectiveness analysis or budget impact model of varegacestat.

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm); [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm); [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/); [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/); [FDA orphan drug designation record for varegacestat (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=968423); [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/); [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/); [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf); [van der Graaf et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_1_ESMO_BriefOralPres_V1.0_21-Sept-2026.pdf); [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/); [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf); [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282); [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/); [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf); [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/); [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf); [Vermont Attorney General new drug report (2024)](https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf); [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf); [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
